Special Issue

Basic Studies for Vaccine Development Targeting Virus Infections

Message from the Guest Editors

The first vaccine against a viral infection was developed in 1798 for smallpox by Dr Edward Jenner, who utilized cow pox. This vaccine enabled the eradication of smallpox from the world in 1980. Thus, vaccination is a powerful tool for protection from pathogens, also applicable for the prevention of other diseases, including cancer. Vaccines for many viral infections still need to be developed. Examples of diseases that could be controlled by vaccination are human immunodeficiency virus infection, hepatitis C, respiratory syncytial virus infection, severe acute respiratory syndrome coronavirus-2 disease. This Special Issue focuses on recent progress in the development of vaccines. Also, we welcome application studies of vaccines. This Special Issue aims to contribute to our knowledge of vaccine development and provide an opportunity to spread new information on vaccine research.

Guest Editors

Prof. Dr. Kyoko Tsukiyama-Kohara
Kagoshima University, Kagoshima, Japan

Prof. Dr. Michinori Kohara
Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

Deadline for manuscript submissions

closed (30 November 2021)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/62874

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).